Topic: Strides Arcolab - another Lupin in the making Posted: 24/Dec/2010 at 10:05pm
This company over the years has transformed itself into a specialized Pharma company operating in a high margin niche segment
Strides has the capacity and products registrations (ANDA) and agreements in place, it is a matter of time and scaling up the production to realize the full potential
ROE to expand as most of the capex would start paying
Earning visibility and stability as a result of deals with Pfizer and Glaxo
One of the largest product pipelines in the injectable segment it has 104 ANDA filings and 73 ANDAs awaiting approval
Strides has developed a product pipeline targeting generic and patented products with an opportunity size of US$11b
The product pipeline includes therapeutic segments like oncology, controlled substances, hormones, penems, penicillins and opthalmalogy.
not that it matters but for Rakesh Jhunjhunwala lovers : he owns 1% of the company
Excerpts from Motilal Oswal report
What the below report doesn’t capture is the immense opportunity of the product pipeline which could catapult the ROE to that of the likes of Lupin once the supply of registered products starts
At similar valuations why should we not look at Torrent Pharma, which has much better financials, is a more integrated pharma company (New drugs, domestic, formulations, exports and CRAMS) and has similar growth prospects. Last 3 years EPS for Torrent has grown at 33%.
Torrent is also a very good play
infact there is a good possibility that Torrent could be sold out like Piramal
Strides has made massive investments in 2006 - 2009 and would continue it till 2012
so the excitement comes from the impending expansion in ROE 2012 and beyond where as Torrent already has a healthy ROE
Strides is more of a play on US healthcare policy where the likes of Pfizer would source their products from India
where as Torrent has a mixed bag of themes
Originally posted by nav_1996
At similar valuations why should we not look at Torrent Pharma, which has much better financials, is a more integrated pharma company (New drugs, domestic, formulations, exports and CRAMS) and has similar growth prospects. Last 3 years EPS for Torrent has grown at 33%.
Joined: 17/Oct/2007
Location: India
Online Status: Offline
Posts: 135
Posted: 25/Dec/2010 at 5:28pm
their history is complicated in respect of creating the wealth towards shareholders. results are always unpredictable. i was tracking the results for 5 years and most of the time there were surprises. at this price mostly all positives are priced in. if some one has view on orchid the tell me because orchid has many assets which might make it lupin
There are only 2 tragedies in market 1st buying a good stock at wrong price 2n buying wrong stock at any price.
Both Strides and Orchid were in investment phase
they were small companies and invested a lot in research and manufacturing facilities
now is the time when their investments should start working for them
ROE for both the companies would expand in next 5 years
Originally posted by bsk0404
their history is complicated in respect of creating the wealth towards shareholders. results are always unpredictable. i was tracking the results for 5 years and most of the time there were surprises. at this price mostly all positives are priced in. if some one has view on orchid the tell me because orchid has many assets which might make it lupin
Strides Arcolabs: Opportunities galore
Priya Kansara Pandya & Ujjval Jauhari / Mumbai December 28, 2010, 0:13 IST
A stake increase in Ascent Pharmahealth augurs well, looking at the opportunities in Australia and South East Asia.
Strides Arcolabs has been buzzing with news flows on FDA approvals and expansion since the start of the current financial year. The stock, too, has moved in tandem, appreciating 25 per cent in the period.
In its most recent move, trying to ensure full control over its Australian subsidiary, Ascent Pharmahealth, Strides last week raised its offer price for minority shareholders from $0.35 to $0.40 (Rs 15.82 to Rs 18.08) a share, translating into a 51 per cent premium over the closing price of Ascent on December 21.
While Strides already holds 58 per cent in Ascent, it plans to raise this to 94 per cent to tap opportunities in Australia and South-East Asia. Ascent sells over 400 drugs in eight countries and plans to expand in South East Asia.
Strides also marked a foray into bio-pharmaceuticals by acquiring 70 per cent stake in the Bangalore-based biotechnology firm, Inbrio solutions, which gives it immediate access to a pipeline of eight bio-similar products that are estimated to have global sales of $ 28 billion. It will make an investment of Rs 65 crore over a years for development and commercialisation of these products.
This year has been good on approvals, with 22 coming in, while another 15 have been filed. Total filings stand at 140, with 53 approvals obtained till now. The company received FDA nod for two strengths of Lidocaine injections in multi-dose vials (it already had approvals for single use vials) and various strengths of Midazolam (an anesthetic) in single dose vials in December alone.
Midazolam will be marketed by Sagent and Strides is developing and supplying 25 injectable products to Sagent to be marketed in the US.
For CY10, analysts expect the company to report a 35 per cent year-on-year jump in revenues to Rs 1,775 crore. At Rs 423.65, the stock trades at 11.7xCY10E estimated earnings.
Pfizer buys Strides' US line-up of 22 drugs for $28 m
Our Bureau
Bangalore, Dec. 30
The pharma industry calls its US market applications ANDAs. Now, 22 such ANDAs or ‘golden eggs' nurtured by Strides Arcolab have hatched into a $28.2- million-plus (Rs 126-crore-plus) nugget for the Bangalore-based drug maker, thanks to the warmth from the large generics market appetite of Pfizer, the world's top drug company.
Pfizer, in a first with an Indian company, has bought 22 of Strides' ANDAs (Abbreviated New Drug Applications). They include 16 approved and six pending filings for sale of off-patent steriles and injections – said to be among the top on Pfizer's list.
The bonus
Strides on Thursday said the deal unlocked the entire portfolio of anti-bacterial and anti-infective injections built up for sales in the US by its marketing venture, Akorn-Strides LLC.
Strides' Rs 10 shares were up marginally to close at Rs 443.30 on the NSE.
The ANDA deal apart, Strides has inked a long-term agreement of undisclosed value with the US major to manufacture and supply the medicine (which then will be sold in the US as Pfizer brands.)
ANDAs are filings that pharma companies make with the US FDA seeking its approval to sell their drugs in that country, the largest drug consumer at $6 billion annual drug sales.
Strides said it “will be entitled to $28.2 million (around Rs 126 crore) in cash as its share of the consideration in addition to entering into supply agreement with Pfizer for manufacture and supply of these products.” The overall deal with the joint venture was for over $63 million.
Mr Arun Kumar, Executive Vice-Chairman and Group CEO of Strides, said, “The divestiture of these products has created significant value for the two joint venture partners. This transaction will further strengthen the strategic partnership between Strides and Pfizer.”
Four of the 22 products are selling in the US. “Akorn-Strides will continue to manufacture and distribute a limited number of the approved products until April 30, 2011,” the company said.
The drugs are part of Strides' 140-odd ANDA filings in the US, of which 53 have been cleared for sales. It has filed 26 through another US company, Sagent Pharma, of which 12 are approved. The rest are through other partners.
Returns significant
Mr T.S. Rangan, Strides Group CFO, told Business Line the returns were significant as the company had invested $2 million while forming the 50:50 venture in 2004 with Akorn Inc. It was to be a vehicle to take its small molecules, mainly steriles or injections, into the US.
Mr Rangan estimated the total US market for the 22 drugs in the range of $550-700 million and said Pfizer could be expected to create a significant volume of sales, thereby driving the production and supply of drugs back home, too.
The portfolio sale to Pfizer would show up in the company's balance sheet for the year-ending December; the money from the manufacturing contract will accrue when the supply was made. The cash would be used to reduce debt. The future of the joint venture would be decided after about three months.
Strides also opened the year with a Pfizer deal, striking a licensed sale arrangement for over 40 patent-expired injectable cancer drugs in January and later expanding the pact to six more countries. A $100-million licensing harvest is on the cards for the group that closed 2009 with turnover of Rs 1,330 crore.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum
Here's why members would love to be a part of theequitydesk.com
Equity Desk focuses on why to buy shares and invest in share rather than what to buy.
Live discussion forum wherein members can discuss the current Indian share Market trend,
BSE Sensex or the Nifty Index.
Have huge cache of information on Indian and World Share Market.
Analysis of Indian stock market, Global events, Investing insights, portfolio
management strategies and thoughts,
Meet investors from round the globe check their investing strategies share experiences and learn
for their experiences on stocks and shares, evaluate opinions on investing in India.
Active Topics
Memberlist
Calendar
Search
Help
Register
Login
IP Logged
